icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
6ZAtQDmvs8Q1e0gZ